Fix up

Inside the generics price-fixing saga in the US

Events that transpired between a few companies in the US generics market may or may not be price-fixing 101. Court documents allow, for the first time, a peek into how it allegedly went down

21/12/17

Gayathri Vaidyanathan

Between 2013 and 2015, generics manufacturers sliced and diced the market for at least 15 drugs and fixed prices. Heritage was the ringleader

Mylan and Heritage employees allegedly exchanged phone calls, text messages and emails discussing Doxy DR in what may amount to textbook anti-competitive behaviour

These allegations were made in court filings last month in a landmark antitrust lawsuit filed by 46 US states against generics manufacturers

But generics manufacturers and their representatives say American authorities are using one bad apple—Heritage—to allege the entire cart is spoilt

game-2391692_1920-1920x1279.jpg

In the spring of 2013, two businessmen from an American subsidiary of an Indian generics manufacturer travelled to Pune to visit their parent company, Emcure Pharmaceuticals. They met Satish Mehta, Emcure’s billionaire chief executive, to discuss the upcoming launch of a drug called Doxy DR. Doxy DR (doxycycline hyclate delayed-release) is a simple molecule—a delayed-release…

To access this post, you must purchase Monthly Recurring, Quarterly or Weekly Product.

Read the full story. Create a free account.

Or subscribe. Why? Let us explain.

Create Account

Already Registered?

Related stories

More stories in /Business & /Healthcare

See all in Business, Reportage & Technology

This story is for subscribers only.
Subscribe for free

Read the full story. Create a free account.

Or subscribe. Why? Let us explain.

Or

By registering, you will be signed-up for an account which gives you access to a free story published once a week and archives of all our free stories. You will also receive a daily newsletter sent to your inbox. To unsubscribe, please visit the profile section in your account.

What you get

Access all free stories

100+ archived free stories, and all upcoming ones too.

Paid story summaries

Read an exclusive 200 word summary for all our paid stories.

Daily Newsletters

Our world-renowned emails, in your inbox, every day.

Or get full access to all our stories

About subscriptions

Already Registered? Login

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

200+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs

    See all results for Ken

    No results found for Ken.